Last reviewed · How we verify

urinary hCG (u-hCG)

Merck KGaA, Darmstadt, Germany · Phase 3 active Small molecule ✓ Verified May 2026

urinary hCG (u-hCG) is a Small molecule drug developed by Merck KGaA, Darmstadt, Germany. It is currently in Phase 3 development for Pregnancy confirmation.

Urinary hCG is a diagnostic test that detects the presence of human chorionic gonadotropin in urine.

Urinary hCG is used as an ovulation trigger in IVF, with studies comparing its effectiveness to recombinant hCG. It is a small molecule that has been studied for its effects on embryonic development, pregnancy, and complications associated with artificial fertilization.

Likelihood of approval
61.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • Big-pharma sponsor +3.0pp
    Merck KGaA, Darmstadt, Germany is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameurinary hCG (u-hCG)
SponsorMerck KGaA, Darmstadt, Germany
ModalitySmall molecule
Therapeutic areaGynecology
PhasePhase 3

Mechanism of action

The test works by detecting the presence of hCG, a hormone produced during pregnancy, in a urine sample. This hormone is produced by the placenta and can be detected in the urine of pregnant individuals. The test is used to confirm pregnancy and monitor fetal development.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about urinary hCG (u-hCG)

What is urinary hCG (u-hCG)?

urinary hCG (u-hCG) is a Small molecule drug developed by Merck KGaA, Darmstadt, Germany, indicated for Pregnancy confirmation.

How does urinary hCG (u-hCG) work?

Urinary hCG is a diagnostic test that detects the presence of human chorionic gonadotropin in urine.

What is urinary hCG (u-hCG) used for?

urinary hCG (u-hCG) is indicated for Pregnancy confirmation.

Who makes urinary hCG (u-hCG)?

urinary hCG (u-hCG) is developed by Merck KGaA, Darmstadt, Germany (see full Merck KGaA, Darmstadt, Germany pipeline at /company/merck-kgaa-darmstadt-germany).

What development phase is urinary hCG (u-hCG) in?

urinary hCG (u-hCG) is in Phase 3.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing